Baiyun Mountain: Revenue Increased by 4.31% in the First Three Quarters, Multi-area Layout and Return to Investors

Baiyun Mountain announced that as of the third quarter of 2025, its revenue increased by 4.31% year-on-year, and its net profit increased by 4.78% year-on-year. The company is focusing on its core business, advancing the development of the industry chain from upstream to downstream, and optimizing procurement and digital transformation. In terms of investment and mergers, Guangzhou Pharmaceuticals' Phase II Fund acquired 7.49 billion yuan to acquire 11.04% of the shares of Nanjing Pharmaceuticals, and Guangzhou Pharmaceuticals won the 100% equity of Zhejiang Pharmaceutical Industry with 5 billion yuan. In terms of innovation, in the first 11 months, new national-level platforms were added, and 27 new product development projects were added. In terms of dividends, the company distributed 13.01 billion yuan in dividends in 2024, accounting for 45.87%; in the first half of 2025, 6.5 billion yuan in dividends were distributed, accounting for 22.93%. The company is actively involved in information disclosure, social responsibility, corporate governance, and other aspects.